News

Archer-Daniels-Midland: We Are Again Right On Target, Slowdown Is Part Of Normalization

4 Mins read

Investment Thesis

Review

We initially covered Archer-Daniel-Midland at $89.41 in February this year with a “Sell” rating, and it subsequently realized an 18% decline to $72.62 by June. At that point, we changed our rating to “Hold”, expecting the price movement

Read the full article here

Related posts
News

Halozyme Therapeutics, Inc. (HALO) Discusses to Acquire ElektrofiConferenceCallTranscript

1 Mins read
Follow Play Earnings CallPlay Earnings Call Halozyme Therapeutics, Inc. (NASDAQ:HALO) Halozyme to Acquire Elektrofi Conference Call October 1, 2025 8:30 AM EDT…
News

Australian Foundation Investment Co (AFOVF) Shareholder/Analyst Call Transcript

1 Mins read
Company Participants Craig DrummondRobert Freeman – MD, CEO & DirectorDavid PeeverMatthew Rowe – Company SecretaryAndrew J. Porter – CFO & Company SecretaryGeoffrey…
News

Unilever: Strong Brands But Fragile Financials – Why I’m Bearish (NYSE:UL)

1 Mins read
This article was written by Follow I am a UK-based equity enthusiast and private investor with a professional background in finance. With…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *